Comparative Pharmacology
Head-to-head clinical analysis: AMERSCAN MDP KIT versus NEPHROSCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMERSCAN MDP KIT versus NEPHROSCAN.
AMERSCAN MDP KIT vs NEPHROSCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m medronate is a bone-seeking radiopharmaceutical that localizes in bone by chemisorption to hydroxyapatite crystals, particularly in areas of increased osteoblastic activity.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
Intravenous administration of 10-20 mCi (370-740 MBq) for adult bone imaging. Administer 2-4 hours prior to imaging.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
None Documented
None Documented
Terminal elimination half-life: approximately 6 hours (range 4-8 hours) for the diphosphonate component; reflects clearance from bone and renal elimination.
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Renal: approximately 50-60% unchanged within 2-3 hours post-injection; biliary/fecal: negligible (<5%). The remainder is retained in bone (up to 40%) with slow release.
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical